45 related articles for article (PubMed ID: 17083991)
1. Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.
Ehrenfeld M; Segeth F; Mantwill K; Brockhaus C; Zhao Y; Ploner C; Kolk A; Gschwend JE; Nawroth R; Holm PS
J Virol; 2023 Jun; 97(6):e0037023. PubMed ID: 37219458
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus.
Gomez-Gutierrez JG; Rao XM; Zhou HS; McMasters KM
Virology; 2012 Nov; 433(2):538-47. PubMed ID: 23021422
[TBL] [Abstract][Full Text] [Related]
3. Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.
Dorer DE; Holtrup F; Fellenberg K; Kaufmann JK; Engelhardt S; Hoheisel JD; Nettelbeck DM
PLoS One; 2011; 6(11):e27934. PubMed ID: 22140489
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
Dyer A; Schoeps B; Frost S; Jakeman P; Scott EM; Freedman J; Jacobus EJ; Seymour LW
Cancer Res; 2019 Jan; 79(2):331-345. PubMed ID: 30487139
[TBL] [Abstract][Full Text] [Related]
5. Biology of ovine adenovirus infection of nonpermissive cells.
Kümin D; Hofmann C; Rudolph M; Both GW; Löser P
J Virol; 2002 Nov; 76(21):10882-93. PubMed ID: 12368331
[TBL] [Abstract][Full Text] [Related]
6. Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation.
Taverner WK; Jacobus EJ; Christianson J; Champion B; Paton AW; Paton JC; Su W; Cawood R; Seymour LW; Lei-Rossmann J
Mol Ther Oncolytics; 2019 Dec; 15():117-130. PubMed ID: 31890865
[TBL] [Abstract][Full Text] [Related]
7. Retroviral vectors containing Tet-controlled bidirectional transcription units for simultaneous regulation of two gene activities.
Loew R; Vigna E; Lindemann D; Naldini L; Bujard H
J Mol Genet Med; 2006 Jul; 2(1):107-18. PubMed ID: 19565004
[TBL] [Abstract][Full Text] [Related]
8. Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer.
Zhang J; Xiao Y; Zhang J; Yang Y; Zhang L; Liang F
J Transl Med; 2024 Jan; 22(1):3. PubMed ID: 38167076
[TBL] [Abstract][Full Text] [Related]
9. Chemogenetic ON and OFF switches for RNA virus replication.
Heilmann E; Kimpel J; Hofer B; Rössler A; Blaas I; Egerer L; Nolden T; Urbiola C; Kräusslich HG; Wollmann G; von Laer D
Nat Commun; 2021 Mar; 12(1):1362. PubMed ID: 33649317
[TBL] [Abstract][Full Text] [Related]
10. Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.
Nakashima H; Chiocca EA
J Virol; 2014 Jan; 88(1):345-53. PubMed ID: 24155386
[TBL] [Abstract][Full Text] [Related]
11. A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate.
Rao V; Heard JC; Ghaffari H; Wali A; Mutton LN; Bieberich CJ
Prostate; 2012 Jul; 72(10):1045-51. PubMed ID: 22297979
[TBL] [Abstract][Full Text] [Related]
12. Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting.
Fang YX; Zhang XB; Wei W; Liu YW; Chen JZ; Xue JL; Tian L
Mol Biotechnol; 2010 May; 45(1):71-81. PubMed ID: 20108058
[TBL] [Abstract][Full Text] [Related]
13. Cellular targeting for cochlear gene therapy.
Ryan AF; Mullen LM; Doherty JK
Adv Otorhinolaryngol; 2009; 66():99-115. PubMed ID: 19494575
[TBL] [Abstract][Full Text] [Related]
14. Mutant sodium channel for tumor therapy.
Tannous BA; Christensen AP; Pike L; Wurdinger T; Perry KF; Saydam O; Jacobs AH; García-Añoveros J; Weissleder R; Sena-Esteves M; Corey DP; Breakefield XO
Mol Ther; 2009 May; 17(5):810-9. PubMed ID: 19259066
[TBL] [Abstract][Full Text] [Related]
15. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.
Curtin JF; Candolfi M; Xiong W; Lowenstein PR; Castro MG
Mol Cancer Ther; 2008 Mar; 7(3):439-48. PubMed ID: 18347132
[TBL] [Abstract][Full Text] [Related]
16. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W
J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991
[TBL] [Abstract][Full Text] [Related]
17. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
18. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
19. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication.
Fechner H; Wang X; Srour M; Siemetzki U; Seltmann H; Sutter AP; Scherübl H; Zouboulis CC; Schwaab R; Hillen W; Schultheiss HP; Poller W
Gene Ther; 2003 Sep; 10(19):1680-90. PubMed ID: 12923567
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
